Jan 08, 2024 / 11:00PM GMT
Eric Joseph JPMorgan-Analyst
All right. Good afternoon. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Nurix Therapeutics, and presenting on behalf of the company is CEO, Arthur Sands. There is a Q&A session after the presentation. If you got a question, we'll bring a mic to you. For those tuning in via the webcast, you can also submit questions via the portal. So with that, Arthur, thanks for joining us.
Arthur Sands Nurix Therapeutics Inc-President - CEO, and Board Director
Thank you, Eric. And I'd like to thank the entire JPMorgan team for inviting us, and for another great JPMorgan conference this year. I will be making certain forward-looking statements, and we refer you to our filings with the SEC regarding the risk factors that face our business.
So at Nurix, we are focused on targeted protein modulation, a new approach to making small molecule agents that can do one of two things -- either harness any E3 ligase as pictured here in the center of the screen -- harness it in order
Nurix Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers